Category: news

Category: news

Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma
09/26/2019 news admin

September 23, 2019 06:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. SHANGHAI, Sept. 23, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today
Details

Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial and Hires Medical Monitor
09/26/2019 news admin

September 13, 2019 15:58 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) —  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today
Details

Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors
09/26/2019 news admin

August 30, 2019 08:41 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details

Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors
09/01/2019 news admin

August 30, 2019 08:41 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details

Xynomic Research Institute Has Successfully Designed a Series of Potent RET Kinase Inhibitors
08/20/2019 news admin

August 16, 2019 16:30 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 16, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details

Xynomic Pharma Receives Important Accreditation from Independent Ethics Committees of Leading Chinese Cancer Hospitals
08/14/2019 news admin

August 07, 2019 16:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 07, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details

Xynomic Pharma Will Present at 3rd World-China Immunotherapy & Gene Therapy Congress
07/26/2019 news admin

July 26, 2019 12:29 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, July 26, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage U.S.-China oncology drug
Details

Xynomic Completes Pre-IND Meeting with US FDA for XP-102, a Novel Pan-RAF Inhibitor against Colorectal Cancer and Lung Cancer
06/14/2019 news admin

RALEIGH, N.C. and SHANGHAI, June 12, 2019 (GLOBE NEWSWIRE) —  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that it recently held a pre-IND meeting with the
Details

Xynomic Pharma 2019 ASCO Annual Meeting Abstracts
Image 05/16/2019 news admin

Xynomic Pharmaceuticals Holdings, Inc. (Nasdaq: XYN), a clinical stage US-China oncology drug development company, and its collaborators will present at the American Society of Clinical Oncology (“ASCO”) 2019 Annual Meeting to be held in Chicago from May 31, 2019 – June
Details

Mr. Y. Mark Xu, Chairman of Xynomic Pharma Participated in the “BioPharma Investment and Partnering in China” Panel Discussion Hosted by Bayer
Image 04/02/2019 news admin

On Thursday, March 28th, Bayer, ChinaBio and Shanghai Healthcare Drinks held a discussion panel entitled “BioPharma Investment and Partnering in China”. The event was hosted by Bayer at its Shanghai Pudong Office, where it brought
Details